Can We Trust the FDA? Marty Makary on Science, Power & Patients

Key Takeaways Copied to clipboard!

• FDA Commissioner Marty Makary is driving significant internal reforms, announcing 42 major changes in 10 months to challenge the status quo, speed up drug approvals, and increase transparency, such as making rejection letters public.  Copied to clipboard!
• The administration views the US as losing the biotech race against China due to slow regulatory processes, particularly concerning IRB approvals and hospital contracting for clinical trials, and is prioritizing streamlining these external bottlenecks.  Copied to clipboard!
• Makary advocates for a fundamental shift in FDA and NIH priorities away from dogma and towards root cause research (like nutrition and environment) and modernizing clinical trial design using tools like Bayesian statistics and reducing animal testing requirements.  Copied to clipboard!
• The FDA, under new leadership, is aggressively pushing to move many safe, non-abuse-potential drugs from prescription-only to over-the-counter status to increase price transparency and bypass complex Pharmacy Benefit Manager (PBM) schemes.  Copied to clipboard!
• The administration is cracking down on misleading pharmaceutical advertising by enforcing regulations on 'fair balance' and closing loopholes that allow companies to omit risk information, exemplified by issuing 1,500 enforcement letters where the previous administration issued zero.  Copied to clipboard!
• The FDA is prioritizing common sense and speed in regulation, particularly for AI decision support tools and wearables, by creating clear consumer lanes while still requiring validation for medical-grade claims, and is actively seeking game-changing scientific breakthroughs like cures for Type 1 diabetes and ALS.  Copied to clipboard!

Segments Expand All Collapse All

Makary’s FDA Appointment Background

Copied to clipboard!

(00:00:00)

• Key Takeaway: Marty Makary secured the FDA Commissioner role following his successful advocacy for hospital price transparency during the first Trump administration.
• Summary: Makary’s interest in the FDA role stemmed from his prior work on healthcare quality, transparency, and price, including writing a book that led to an invitation to the White House. He was instrumental in implementing the hospital price transparency executive order. President Trump called him days after the election to offer the position.

Critique of COVID-19 Dogma

Copied to clipboard!

(00:02:05)

• Key Takeaway: Makary strongly criticized the ‘sociology of medical dogma’ during COVID-19, citing cloth masks on toddlers and ignoring natural immunity as examples of scientific dishonesty.
• Summary: He condemned paternalism and the suppression of questioning ideas during the pandemic, specifically mentioning mandates for young college students and the prolonged school closures. He views his current role as essential for rebuilding public trust in health institutions following these events.

FDA Reform and Challenging Status Quo

Copied to clipboard!

(00:03:21)

• Key Takeaway: The FDA has announced 42 major reforms in 10 months, driven by internal feedback from anonymous reviewers who feel constrained by supervisory presence.
• Summary: Reforms aim to challenge the status quo, such as the 10-to-12-year timeline for new drug approval, which Makary finds unacceptable. A key reform was making FDA rejection letters public to create accountability, a change discussed for 30 years but only recently implemented.

Addressing FDA Staffing and Morale

Copied to clipboard!

(00:06:03)

• Key Takeaway: Despite reports of chaos following staffing cuts, the FDA’s turnover rate remains at the 10-year baseline, and the agency is actively hiring 1,050 new scientists for ambitious new pathways.
• Summary: Staff cuts focused on duplicative services in HR and IT, not on scientific reviewers, who were all retained. Makary’s priority is delivering cures faster, contrasting with the previous commissioner’s focus on fighting misinformation. The agency hit 100% of its user fee target dates in the past year, indicating operational strength.

US vs. China Biotech Competition

Copied to clipboard!

(00:07:50)

• Key Takeaway: To compete with China’s rapid biotech innovation, the US must streamline clinical trial initiation by centralizing Institutional Review Boards (IRBs) and hospital contracting.
• Summary: China is accelerating Phase 1 trials to four weeks, while US hurdles like IRB reviews can take over a year for simple surveys. The FDA is working to reduce the 60-day wait time for application completeness confirmation to one day using AI modernization.

Accelerating Drug Approval Timelines

Copied to clipboard!

(00:13:14)

• Key Takeaway: The FDA is reducing regulatory burden by moving from a default requirement of two pivotal trials to one, and eliminating mandatory chimpanzee studies for monoclonal antibodies.
• Summary: The shift to one pivotal trial saves companies $100M-$300M and shortens timelines, while eliminating animal testing requirements like chimpanzee studies addresses bioethical concerns and potential misleading data. Modern techniques like computational modeling and ‘organ on a chip’ technology are being adopted to replace outdated animal studies.

Continuous Trials and Post-Market Surveillance

Copied to clipboard!

(00:19:57)

• Key Takeaway: The FDA is moving towards continuous trials using Bayesian statistics and real-time data monitoring to allow for faster approvals and immediate recognition of post-market safety signals.
• Summary: The goal is to move away from submitting massive applications annually to continuous data flow, allowing reviewers to call endpoints as soon as efficacy is established. This continuous observational system aims to prevent tragedies like the Vioxx fallout by catching safety signals in specific subgroups immediately after approval.

Risk Perception and Right to Try

Copied to clipboard!

(00:24:25)

• Key Takeaway: Unnecessary time delays in drug approval carry significant risks to patients awaiting cures, necessitating a balance between absolute safety and speed, which the Right to Try law supports.
• Summary: Makary argues that unnecessary delays, like waiting eight months for chimpanzee studies, risk withholding curative medication. He fully supports the Right to Try law, having signed 100% of requests that came across his desk, provided the companies agree to supply the drug.

Cell and Gene Therapy Manufacturing Flexibility

Copied to clipboard!

(00:26:43)

• Key Takeaway: The FDA is customizing manufacturing requirements (like PPQ runs) for cell and gene therapies to match the bespoke nature of these treatments, moving away from mass-production standards.
• Summary: This change customizes requirements based on the drug and population, reducing the burden of expensive ingredient testing for small-batch, life-saving therapies like those used for rare diseases. This flexibility supports novel pathways, such as the ‘Plausible Mechanism Pathway’ used for therapies like Baby KJ’s gene editing treatment.

Reforming the Food Pyramid Dogma

Copied to clipboard!

(00:33:14)

• Key Takeaway: The previous US food pyramid was scientifically inaccurate, driven by dogma that demonized natural fats and promoted refined carbohydrates, leading to widespread insulin resistance in children.
• Summary: Nutrition science is described as one of the most corrupted fields, resulting in dietary guidance that caused 38% of US children to develop prediabetes or diabetes. The new guidance flips the pyramid, emphasizing protein intake (which was half the required amount) and focusing on ‘real food’ quality over simple calorie counting.

GLP-1s and Obesity Epidemic Failure

Copied to clipboard!

(00:41:32)

• Key Takeaway: The obesity epidemic, evidenced by 40% of American children having chronic disease, confirms the failure of past food guidance, making GLP-1 drugs a necessary intervention mimicking natural satiety hormones.
• Summary: GLP-1 drugs reduce insulin resistance and inflammation, explaining their observed benefits across various indications beyond weight loss. Makary notes that the ultra-processed, chemicalized food environment has created addictive eating patterns that are not simply a matter of willpower.

Reallocating NIH Research Funding

Copied to clipboard!

(00:44:19)

• Key Takeaway: The Trump administration has not cut NIH funding but is reallocating it away from descriptive DEI research and genetic focus toward studying root causes like food, sleep, and environmental exposures.
• Summary: Funding is shifting away from areas like the Wuhan lab research and descriptive health disparity studies (which consumed 14% of grants) toward actionable areas like ‘food as medicine.’ This shift aims to address the underlying causes of chronic disease rather than solely focusing on genetic treatments or symptom management.

Revisiting the Childhood Vaccine Schedule

Copied to clipboard!

(00:49:56)

• Key Takeaway: The US vaccine schedule was an international outlier recommending 72 doses by age 18, prompting the creation of a ‘core essential’ list of 38 doses to restore public trust lost during the COVID-19 response.
• Summary: The administration created a hierarchy of essential vaccines to prevent parents from rejecting all shots due to distrust over dogma like mandatory boosters for healthy individuals. Medicine must show humility and meet patients where they are, similar to recommending ultrasounds instead of mammograms for hesitant patients.

Lowering Drug Prices via Competition

Copied to clipboard!

(00:59:14)

• Key Takeaway: Drug prices are being aggressively lowered through implementing ‘most favored nation status’ pricing and streamlining FDA approval for biosimilars to foster competition against expensive biologics.
• Summary: The US is demanding prices matching the lowest in the developed world, which is projected to drop GLP-1 drug costs significantly. Furthermore, reducing the time and cost for biosimilar approval (from 5-8 years/$300M down to 2.5 years) will open the market to competition, bypassing PBM complexities.

Biosimilars and Prescription Paternalism

Copied to clipboard!

(01:02:40)

• Key Takeaway: The lack of significant price reduction for Humira after biosimilar entry suggests implied price collusion, necessitating a flood of biosimilars to drive competition.
• Summary: The high price of Humira did not drop substantially after the first biosimilar arrived, implying potential price collusion. A large influx of biosimilars is needed to force prices down. Requiring prescriptions for many drugs is seen as medical paternalism, similar to past resistance against home pregnancy and COVID testing availability.

Over-the-Counter Drug Transition

Copied to clipboard!

(01:03:41)

• Key Takeaway: Moving drugs over the counter lowers prices by introducing shelf competition and bypassing the opaque financial games played by Pharmacy Benefit Managers (PBMs).
• Summary: Placing drugs on a store shelf introduces price transparency, which keeps prices in check through consumer shopping competition. This transition bypasses the complex money games involving PBMs, brokers, and employers that inflate prescription costs. The FDA has appointed new leadership to the Office of Non-Prescription Drugs to facilitate this mass transition based on criteria like lack of abuse potential and no need for lab testing.

Insurance Modernization for OTC Drugs

Copied to clipboard!

(01:06:09)

• Key Takeaway: Insurance companies must modernize their reimbursement schemes to cover non-prescription drugs, a necessary step since insurers often own the PBMs.
• Summary: Insurance companies must update their outdated reimbursement constructs that separate prescription and non-prescription drug coverage. This modernization is critical because insurance companies frequently own the PBMs involved in the current complex payment structures. Moving medications OTC is a massive priority for the administration this year, with a goal set for 2026.

Pharmaceutical Advertising Critique

Copied to clipboard!

(01:07:53)

• Key Takeaway: TV advertising for biologics creates misleading demand, prompting the FDA to enforce ‘fair balance’ rules and close the ‘adequate provision’ loophole that allows risk information to be hidden online.
• Summary: While advertising raises awareness, it often creates misleading impressions, causing patients to demand expensive biologics that may not be indicated for them. The FDA is enforcing regulations that ads must not mislead and must provide a ‘fair balance’ of information. The agency is closing the ‘adequate provision’ loophole, which previously allowed companies to list side effects only on a website.

AI Regulation and Wearables

Copied to clipboard!

(01:11:52)

• Key Takeaway: The FDA is establishing clear guidance for AI decision support and wearables, distinguishing between consumer information and medical-grade claims requiring FDA validation.
• Summary: The FDA cannot regulate AI information at the rate it is produced, requiring a common-sense demarcation between general AI output and automated health interventions. New guidance creates a clear consumer lane for AI decision support and wearables, but medical-grade claims require FDA review and validation data. Wearables measuring physiologic parameters like heart rate and glucose will become more accessible unless they claim medical-grade accuracy.

Alternative Proteins and GRAS Loophole

Copied to clipboard!

(01:13:50)

• Key Takeaway: The FDA is closing the ‘Generally Recognized As Safe’ (GRAS) loophole, which allowed self-declaration of safety for novel chemicals, shifting toward a European model where safety must be proven before introduction.
• Summary: The GRAS system, intended for simple items like salt, was abused, allowing numerous novel chemicals into ultra-processed foods without rigorous safety demonstration. The FDA is initiating regulatory processes to close this loophole, aligning closer to the European ‘guilty until proven innocent’ standard for new chemicals. This change addresses concerns over inflammatory responses linked to ingesting denatured proteins and non-naturally occurring molecules.

Autism Drivers and Microbiome Research

Copied to clipboard!

(01:19:00)

• Key Takeaway: Rising autism diagnoses may be linked to environmental factors, potentially involving an autoimmune phenomenon blocking folate receptors or significant damage to the microbiome from modern practices.
• Summary: The dramatic increase in autism diagnoses, especially in young boys, suggests environmental factors are at play, as older generations did not show these rates. One hypothesis involves an autoimmune response blocking folate receptors, which treatments like leukavorin might bypass to allow neural development. The modern torture of the microbiome via C-sections, formula, and excessive antibiotics causes inflammation that may manifest as mood disorders or contribute to autism.

Frontiers of Health Science

Copied to clipboard!

(01:25:20)

• Key Takeaway: The FDA aims to be a fast referee for transformative treatments, prioritizing cures for Type 1 diabetes, powerful ALS treatments, and effective PTSD therapies over incremental non-inferiority studies.
• Summary: The FDA is focused on accelerating revolutionary treatments, citing examples like gene therapy for deafness and new multiple myeloma drugs that received immediate priority vouchers. Key areas for breakthroughs include cures for Type 1 diabetes, powerful treatments for ALS, and effective therapies for PTSD, given the high rate of veteran suicide. The agency is actively engaging scientific reviewers to identify and fast-track novel mechanisms that represent a true leap forward.